Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $5.55
Previous CloseN/A
Volume240.10K
Average Volume (3M)506.96K
Market Cap
$274.17M
Enterprise Value-$35.46M
Total Cash (Recent Filing)$325.55M
Total Debt (Recent Filing)$11.64M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Oct 29, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding59,089,130
10 Day Avg. Volume393,639
30 Day Avg. Volume506,956
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-0.17
Enterprise Value/Gross Profit-0.19
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$20.00Price Target Upside333.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVanda reported its 1Q25 financial results with a top-line revenue totaling $50M, beating the forecast of $45M.
Product PipelineVanda's neuropsychiatry portfolio, including iloperidone and milsaperidone, is expected to drive significant future sales growth, potentially exceeding $1 billion by 2030.
Regulatory ApprovalThe FDA has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for treatment of polycythemia vera (PV).
Bears Say
Financial LossThe company recorded a net loss of $0.46 per share vs. the forecast for a net loss of $0.35 per share.
Generic CompetitionHETLIOZ franchise continued to demonstrate resilience in the face of generic competition.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.81 and its highest was $5.54 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $274.17M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 53 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Jul 31, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.357 by -$0.103.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.43.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 59,089,130 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.357. Following the earnings report the stock price went down -8.779%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (333.84% Upside)
$20.00 (333.84% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 17.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.66%
12-Months-Change
Fundamentals
Return on Equity
-13.01%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. Significant growth in Fanapt revenue and prescriptions, as well as promising regulatory advancements for Bysanti, were overshadowed by increased net losses, declining HETLIOZ and PONVORY revenues, and higher operating expenses. While there are strong strategic developments, financial challenges remain significant.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$20.00
▲(333.84% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
16.53% Mutual Funds
12.22% Other Institutional Investors
50.88% Public Companies and
Individual Investors